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Abstract
Interleukin-1b (IL-1b) is a pro-inflammatory cytokine that contributes to neuronal injury in various degenerative
diseases, and is therefore a potential therapeutic target. It exerts its biological effect by activating the interleukin-1
receptor type I (IL-1RI) and recruiting a signalling core complex consisting of the myeloid differentiation primary
response protein 88 (MyD88) and the IL-1R accessory protein (IL-1RAcP). This pathway has been clearly described
in the peripheral immune system, but only scattered information is available concerning the molecular
composition and distribution of its members in neuronal cells. The findings of this study show that IL-1RI and its
accessory proteins MyD88 and IL-1RAcP are differently distributed in the hippocampus and in the subcellular
compartments of primary hippocampal neurons. In particular, only IL-1RI is enriched at synaptic sites, where it co-
localises with, and binds to the GluN2B subunit of NMDA receptors. Furthermore, treatment with NMDA increases
IL-1RI interaction with NMDA receptors, as well as the surface expression and localization of IL-1RI at synaptic
membranes. IL-1b also increases IL-1RI levels at synaptic sites, without affecting the total amount of the receptor in
the plasma membrane. Our results reveal for the first time the existence of a dynamic and functional interaction
between NMDA receptor and IL-1RI systems that could provide a molecular basis for IL-1b as a neuromodulator in
physiological and pathological events relying on NMDA receptor activation.
Findings
Interleukin-1b (IL-1b) is a pro-inflammatory cytokine
that is involved in the pathogenesis of a number of neu-
rological disorders, possibly as a modulator of glutama-
tergic response [1]. This suggestion arises from the
observation that IL-1b is often over-produced in injured
tissues in which there are high levels of glutamate [2-4],
and this over-production has been related to the exacer-
bation of glutamate-driven pathological conditions [4-6].
Various mechanisms have been identified that may
explain the convergence between the IL-1b and gluta-
matergic systems [1], including hyperactivation of the
NMDA receptor (NMDAR). IL-1b increases the activity
of hippocampal neuronal NMDARs by phosphorylating
the GluN2B subunit and thus enhancing NMDA-
induced neuronal death [7]. The same mechanism is
recruited in neurons as a consequence of the IL-1b
released from glia by the HIV-virus glycoprotein gp120
[8], and underlies the pro-convulsive effect of IL-1b [9].
Whatever mechanism may be recruited by IL-1b,t h e
involvement of IL-1RI is suggested by the uncontested
neuroprotective effect of the IL-1 receptor antagonist
(IL-1ra) [4,10].
The binding of IL-1b to IL-1RI in the immune system
leads to its association with the IL-1R accessory protein
(IL-1RAcP) [11] and the myeloid differentiation primary
response protein 88 (MyD88) [12] to form the core of
the IL-1b/IL-1R signalling complex. However, little
information is currently available concerning the mole-
cular composition of the members of the IL-1R com-
plex, or their subcellular distribution and functional
cross-talk with NMDARs in neuronal cells [13-15]. This
is a major gap in our knowledge of the pathological
mechanisms involving IL-1b/IL-1RI in neurons that may
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The distribution of IL-1RI, IL-1RAcP and MyD88,
together with the pre- and post-synaptic markers synap-
tophysin and PSD-95, was investigated in different sub-
cellular compartments purified from adult rat
hippocampi by means of western blotting [16], and by
means of confocal microscopy of primary hippocampal
neurons.
Subcellular fractionation showed that IL-1RI, MyD88
and IL-1RAcP were present in all of the tested fractions
but, although IL-1RI and MyD88 were particularly
enriched in the postsynaptic density (PSD) fraction
(Figure 1A, left panel), together with PSD-95 and the
GluN1 subunit of the NMDA receptor (Figure 1A, right
panel), only traces of IL-1RAcP were present in the
postsynaptic Triton-insoluble fraction (TIF) and PSD
(Figure 1A, left panel). Confocal imaging showed that
Figure 1 Characterisation of IL-1RI, IL-1RAcP and MyD88 subcellular distributions in rat hippocampi and primary hippocampal
neurons. A: IL-1RI, IL-1RAcP and MyD88, together with markers of the pre-synaptic compartment (synaptophysin) and post-synaptic side (PSD-
95, GluN1) were analysed in various rat hippocampus subcellular compartments by means of western blot. H = homogenate; S1 = low-speed
supernatant; P1 = nuclei-associated membranes; S2 = high-speed supernatant; P2 = crude membrane fraction; Syn = synaptosomes; TIF = Triton-
insoluble postsynaptic fraction; PSD = post-synaptic density. B: DIV14 hippocampal neurons were immunolabelled for IL-1RI, IL-1RAcP and MyD88
(upper panels), and PSD-95 as a post-synaptic marker (middle panels). The bottom panels show the merged images. Scale bar: 10 μM. High-
magnification images are shown at the top of each panel. The antibody specific for IL-1RI was from Santa Cruz Biotechnology, Inc (Santa Cruz,
CA) (M20) and its specificity has been tested by pre-absorption with the blocking peptide (data not shown).
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post-synaptic compartment, as shown by the high
degree of co-localisation with PSD-95 (34.3% ± 3.7%;
Figure 1B, left panels). MyD88 was uniformly distributed
along the neurons and moderately co-localised with
PSD-95 (15.6% ± 2.8%; Figure 1B, right panels). IL-
1RAcP labelling was intense and diffuse in the somatic
cytoplasm of cultured neurons, and low and diffuse
along the dendrites, and hardly co-localised with PSD-
95 (4.1% ± 1.9%; Figure 1B, central panels). Overall,
these data suggest that there is a different subcellular
distribution of the members of the IL-1R complex pro-
tein in neurons, with IL-1RI (and, to a lesser extent,
MyD88) being enriched at the post-synaptic sites.
Co-immunoprecipitation experiments involving the
components of the IL-1R complex and the AMPA and
NMDA receptor subunits were performed to assess the
localisation and interactions of IL-1RI within distinct
subdomains of the PSD structure [17]. Protein homo-
genates (200 μg) from rat hippocampi were immuno-
precipitated [18] with antibodies specific for IL-1RI,
for the GluA1 subunit of AMPA receptors, or for the
GluN2B subunit of the NMDA receptor. Each sample
was then evaluated for the presence of: i) IL-1RI, IL-
1RAcP and MyD88; ii) the GluN2B subunit: and iii)
PSD-95. Figure 2A shows that, in hippocampal lysates,
IL-1RI not only co-precipitated with IL-1RAcP and
MyD88, but also with GluN2B; the absence of any
PSD-95 signal in the IL-1RI co-immunoprecipitates
excludes the possibility that, under our experimental
conditions, the co-precipitation of GluN2B reflected
nonspecific immunoprecipitation of insoluble synaptic
proteins. In line with this, GluN2B co-precipitated
with IL-1RI, thus confirming the association between
Figure 2 Interaction between IL-1RI and the GluN2B subunit of NMDA receptors. A: Total homogenate was immunoprecipitated (i.p.) with
antibodies against IL-1RI, GluA1 or GluN2B, and the presence of GluN2B, IL-1RI, PSD-95, IL-1RAcP and MyD88 in the immunocomplex was
evaluated by means of western blot. IL-1RI, IL-1RAcP and MyD88 co-precipitated with GluN2B but not with GluA1. (*) Nonspecific bands were
detected in the No IgG lane. B: GST-IL-1R(CD) and GST-PSD-95(PDZ1-2) fusion proteins, and GST alone were incubated in a pull-down assay with
total homogenate from rat hippocampus. The western blot analysis was performed using the GluN2B antibody. C: Hippocampal cultures were
exposed in the absence or the presence of IL-1b (30 minutes, 0.05 ng/ml) or NMDA (10 minutes, 50 μM). Neuronal lystes were
immunoprecipitated with anti-IL-1RI, and the presence of GluN2B and IL-1RI in the immunocomplex was evaluated by means of western blot.
Treatment with NMDA but not with IL-1b led to a significant increase in the IL-1b/GluN2B complex (p < 0.05 NMDA vs control).
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of the members of the IL-1R complex was detectable
in the immunocomplex of the GluA1 subunit of
AMPA receptors, which suggests a specific interaction
between the GluN2B subunit of the NMDA receptor
and IL-1R complexes (Figure 2A).
The association between IL-1RI and GluN2B was
confirmed by a pull-down assay based on a fusion pro-
tein of the cytoplasmic domain of IL-1RI with GST
(GST-IL-1Rcd) (Figure 2B), which contained the
C-terminal 369-569 aa domain of IL-1RI. As a positive
control, we used a GST-PSD-95 (PDZ1-2) fusion pro-
tein that has been previously shown to bind the
GluN2B subunit of NMDA receptors [18]. Lysates
from rat hippocampal neurons were applied to affinity
beads and extensively washed, after which the bound
material was resolved by SDS-PAGE and underwent
immunoblotting analysis using an antibody raised
Figure 3 Effect of NMDA and IL-1b on IL-1RI subcellular localisation. A: Western blot analysis of the TIF fraction obtained from control,
IL-1b-treated (0.05 ng/ml) and NMDA-treated hippocampal cultures (50 μM). The same amount of proteins was loaded in each lane. IL-1b
increases IL-1RI localization in the Triton-insoluble fraction (TIF) (*p< 0.05) leaving unaffected IL-1RAcP and MyD88 levels. Values are means ± S.E
of 4 independent experiments. B: Western blot of IL-1RI from control, IL-1b-treated (0.05 ng/ml) and NMDA-treated (50 μM) hippocampal
cultures exposed (+BS
3 lanes) or not (-BS
3 lanes) to the cross-linking agent BS
3. IL-1RI high-molecular-weight complexes that didn’t enter the gel
are not shown. C: Hippocampal neurons were either left untreated (control) or treated with IL-1b (0.05 ng/ml, 30 minutes) or NMDA (50 μM)
fixed, and immunolabeled for IL-1RI (green) and PSD-95 (red) as a postsynaptic marker. Data are expressed as percentage of IL-1RI colocalization
with PSD-95 (AIM4.2 software, Zeiss). White arrows indicate PSD-95 positive clusters in the merge panel. Scale bar: 5 μM.
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and PSD-95 (PDZ1-2) associated with the GluN2B
subunit, thus confirming a specific association between
IL-1RI and GluN2B.
As it is well known that the synaptic localisation of
receptors and ion channels, together with their protein-
protein interactions, are modulated in response to var-
ious stimuli, and that they undergo dynamic changes
under physiological and pathological conditions [19,20],
we investigated the possibility that IL-1RI distribution
and interaction with GluN2B may be dynamically modu-
lated. Given the relationship between the IL-1b receptor
complex and NMDAR, we treated primary hippocampal
neurons with IL-1b, 0.05 ng/ml, for 30 min (a concen-
tration that also enhances NMDAR activity) [7] or
NMDA, 50 μM, in ACSF buffer [7]: the NMDA was
applied to the neurons for 10 min, after which the cells
were washed and incubated for a further 20 min in
ACSF buffer. We first tested whether IL1-b and/or
NMDA modulated the interaction between IL-1RI and
the GluN2B subunit of the NMDA receptor (Figure 2C).
IL-1RI was immunoprecipitated from total lysates of pri-
mary hippocampal neurons treated or not with NMDA,
50 μM, or IL-1b, 0.05 ng/ml, and assayed for GluN2B
by means of western blotting (Figure 2C). The results
show that only NMDA significantly increased the inter-
action between IL-1RI and GluN2B (Figure 2C; p < 0.05
NMDA vs control).
We then evaluated whether the members of the IL-1b
receptor complex could be re-distributed in different
neuronal compartments after stimulation with IL-1b or
NMDA. Both NMDA and IL-1b significantly increased
the amount of IL-1RI in the postsynaptic TIF fraction
(Figure 3A; p < 0.05, IL-1b or NMDA vs control). The
treatments did not affect the synaptic distribution of
either IL-1RAcP or MyD88. These results were con-
firmed by confocal microscopy (Figure 3C), which
showed an increase in the co-localisation of IL-1RI with
PSD-95 as quantified in the graph (Figure 3C).
The increase in IL-1RI receptors at the postsynaptic
site may be due to new synthesis and delivery of recep-
tors from the endoplasmic reticulum, or to lateral diffu-
sion from adjacent compartments [19,21], and this was
addressed by carrying out surface expression assays
using the non-cleavable, membrane-impermeable cross-
linking agent BS
3 [22]. Primary hippocampal neurons
were treated with IL-1b,0 . 0 5n g / m l ,o rN M D A ,5 0μM,
and then exposed to BS
3, lysed and blotted for IL-1RI.
The intracellular amount of IL-1RI was reduced by
NMDA but not by IL-1b (p < 0.05, NMDA vs control;
Figure 3B). The reduction in intracellular IL-1RI after
NMDA exposure, together with its increase in the
synaptic fraction, suggests that NMDAR activation
favours the membrane insertion of new IL-1RI.
Alternatively, the increase in IL-1RI in the synaptic
membrane may be attributable to stabilisation of the
complex with NMDAR (within the core of the PSD),
which could prevent lateral movement and/or endocyto-
sis. In either case, a new pool of receptors would be
made available. On the contrary, IL-1b possibly enriches
IL-1RI at post-synaptic sites, promoting its lateral trans-
location (i.e. membrane diffusion) from extra-synaptic
sites; however, this probably does not occur within the
core microdomain of the PSD, as suggested by the
unchanged levels of IL-1RI associated with the NMDAR
complex.
In conclusion, ours are the first findings showing a
molecular interaction between IL-1RI and the GluN2B
subunit of NMDAR, and suggest a new molecular
mechanism by means of which IL-1b and NMDA may
dynamically regulate IL-1RI at post-synaptic sites.
Furthermore, NMDA-dependent activation increases
the amount of IL-1RI inserted into the membrane
capable of interacting with released IL-1b.T h i ss u g -
gests a new molecular mechanism by means of which
IL-1b may contribute to excitotoxicity, thus opening
up new possibilities for targeted inhibition strategies
that can be used in IL-1b/glutamate-driven CNS
diseases.
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